-To determine the effect of early versus delayed treatment with venglustat on the total
kidney volume (TKV) in participants at risk of rapidly progressive ADPKD.
To determine the effect of early versus delayed treatment with venglustat on the renal
function (estimated glomerular filtration rate [eGFR]).
To characterize the safety profile of venglustat.
To evaluate the effect of venglustat on the lens by ophthalmological examination.
To evaluate the effect of venglustat on mood using Beck Depression Inventory-II
Study duration per participant is 25.5 months (maximal). Screening period (when applicable):
up to 2 weeks. Core treatment period: 24 months. Follow-up: 30 days after final dose of the
investigational medicinal product (IMP) (venglustat).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.